Best Penny Stocks Under 5 Cents Right Now

CURO Group Holdings Corp., together with its subsidiaries, provides consumer finance products in the United States and Canada. The company offers secured and unsecured installment loans, revolving line of credit, and single-pay loans; and credit protection insurance, check cashing, money transfer, foreign currency exchange, and other ancillary financial products and services, as well as reloadable prepaid debit cards and demand deposit accounts. The company also provides loans through online. It operates under the Covington Credit, Heights Finance, Quick Credit, Southern Finance, First Heritage Credit, Cash Money, LendDirect, and Flexiti brands. The company was formerly known as Speedy Group Holdings Corp. and changed its name to CURO Group Holdings Corp. in May 2016. CURO Group Holdings Corp. was founded in 1997 and is headquartered in Chicago, Illinois.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Shapeways Holdings, Inc. facilitates the design, manufacture, and sale of 3D printed products in the United States and internationally. The company offers an end-to-end digital manufacturing platform on which the users can transform digital designs into physical products under the Otto brand; additive manufacturing services, such as 3D printing, rapid prototyping, and design services; and traditional manufacturing services, including injection molding, sheet metal, urethane and vacuum casting, CNC machining, and machine tooling. It also provides selective laser sintering materials, which include nylon 12, thermoplastic polyurethane, polypropylene, thermoplastic elastomer, and nylon 11; binder jetting materials consisting of stainless steel, steel, and sandstone; multi-jet fusion materials; stereolithography materials, such as accura 60, accura xtreme, and accura xtreme 200; selective laser melting material, including aluminum; material jetting materials, such as fine detail plastic, multi-color polyjet, and high definition full color; and wax casting materials comprising copper, platinum, gold, silver, bronze, brass, rhodium, and gold plated brass. It serves the medical, consumer, robotics, architecture, aerospace, gaming, drones, education, and jewelry industries. Shapeways Holdings, Inc. was founded in 2008 and is based in New York, New York.

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Movella Holdings Inc. operates as a full-stack provider of sensors, software, and analytics that enable the digitization of movement in the United States. Its real-time character movement in digital environments transforms movement into digital data that provides actionable insights. The company offers Xsens 3D Body Motion Systems comprises wearable sensor systems and motion capture solutions, including MVN Animate or MVN Analyze software, a full-body wearable sensor system, which captures the motion of the human body. It also provides Xsens sensor modules that enables customers to accelerate the development of motion-based applications; and DOT wearables for analysis and reporting of human kinematics. In addition, the company offers Kinduct human performance platform that provides biomechanical, biometric, and objective data for athletic performance, wellness, and injury risk. It serves the entertainment, health and sports, and automation and mobility markets. Movella Holdings Inc. is based in Henderson, Nevada.

MetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.

Eguana Technologies Inc. designs and manufactures residential and commercial energy storage systems for fuel cell, photovoltaic, and battery applications in Canada, Asia, Australia, Europe, and the United States. The company provides its products under the Enduro, Evolve, and Elevate brand names. The company was formerly known as Sustainable Energy Technologies Ltd. and changed its name to Eguana Technologies Inc. in September 2013. Eguana Technologies Inc. is headquartered in Calgary, Canada.

Horizonte Minerals Plc, together with its subsidiaries, engages in the exploration and development of mineral projects in Brazil. The company primarily explores for nickel deposits, as well as cobalt deposits. It holds 100% interest in the Araguaia ferronickel; and the Vermelho Nickel-Cobalt project in the eastern part of the Carajás mining district. The company is headquartered in London, the United Kingdom.

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

COMSovereign Holding Corp. provides various solutions for network operators, mobile device carriers, governmental units, and other enterprises worldwide. The company offers packet microwave solutions that transmit broadband voice, video, and data, as well as enable service providers, government agencies, enterprises, and other organizations; harmony enhanced MC; fastback intelligent backhaul radio (IBR); and in-band full-duplex technology. It also provides tethered drones and aerostats for use in intelligence, surveillance, reconnaissance, and tactical communication, as well as communication platform for national defense and security customers; and edge compute capable 4G LTE and 5G network radio. In addition, the company offers repairs, support and maintenance, drones, consulting, and warranties as well as other services. The company was formerly known as Drone Aviation Holding Corp. and changed its name to COMSovereign Holding Corp. in November 2019. COMSovereign Holding Corp. was incorporated in 2014 and is based in Tucson, Arizona.

Kaspien Holdings Inc. operates an e-commerce services provider. Its platform of software and services enable brand's online distribution channel on digital marketplaces, such as Amazon, Walmart, Target, and others. The company's technology-enabled retailer that delivers brand partners across Amazon.com US, Amazon.com Canada, Target.com, and Walmart.com online marketplaces. The company was formerly known as Trans World Entertainment Corporation and changed its name to Kaspien Holdings Inc. in September 2020. Kaspien Holdings Inc. was incorporated in 1972 and is headquartered in Spokane, Washington.

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.